Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol

Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against GRAIL, Inc. (“GRAIL” or the “Company”) (NASDAQ:GRAL) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Grail common stock between May 13, 2025, and February 19, 2026, both dates inclusive (the “Class Period”). Investors have until August 4, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The Complaint alleges that Defendants provided materially false and misleading statements and/or concealed material adverse facts concerning the true state of the Company’s NHS Galleri trial following the reveal of the top-line results covering the first screening round. The Complaint alleges that Defendants have since attested that the trial -- as executed within the three-year follow-up period -- was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers; Defendants disclosed the trial period, and thus the screening duration, was apparently insufficient to demonstrate whether the primary endpoint was achievable.

The Complaint continues to allege that Defendants further repeatedly refused to provide detailed topline results or other data from the NHS-Galleri study, potentially concealing known trendlines which arguably suggested either a longer timeline would be necessary or otherwise that the probability of achieving the statistical reduction in Stage III & IV cancers by the trial’s end had been reduced.

On February 19, 2026, GRAIL announced results for its NHS-Galleri trial, which evaluated annual multi-cancer screening with GRAIL’s Galleri test, revealing that “[t]he primary endpoint of statistically significant Stage III-IV reduction was not observed.” On this news, the price of GRAIL stock fell significantly.

If you purchased or otherwise acquired GRAIL shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.